Dyne Therapeutics reports clinical data from its myotonic dystrophy type 1 treatment
Dyne Therapeutics (NASDAQ:DYN) reported clinical data from its ongoing Phase 1/2 trial of DYNE-101 in patients with myotonic dystrophy type 1. Shares down about 22% in early trade. DYNE-101 continued ...
Dyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1
(RTTNews) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1). Myotonic dystrophy ...
abp LIVE1dOpinion
Opinion: Understanding FSHD — The 3rd Most Common Muscular Dystrophy — And The Importance Of Early Diagnosis
An estimated 1 in 8,000 individuals, or 870,000 people worldwide, are affected by Facioscapulohumeral muscular dystrophy ...
ucdavis.edu3d
THE DOWNLOAD: Clinical Trial Documentary, 2024 Recap
UC Davis Health has premiered a new documentary on a family’s urgent journey across the globe to get their toddler in a clinical trial for patients with Duchenne Muscular Dystrophy, or DMD.
PharmiWeb5d
Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (Vamorolone) in countries where the product ...
The Pharma Letter5d
Santhera partners with Clinigen to expand Agamree access
Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.
Pharmaceutical Technology6d
Irodanoprost by Mesentech for Duchenne Muscular Dystrophy: Likelihood of Approval
Irodanoprost is under clinical development by Mesentech and currently in Phase I for Duchenne Muscular Dystrophy.